Sector News

GSK to shut Bangladesh drug making factory by end-2018

July 30, 2018
Life sciences

GlaxoSmithKline will shut its drug manufacturing operations in Bangladesh by the end of this year and will continue with its healthcare business, the managing director of its local businesses said on Friday.

Globally GSK’s pharmaceuticals business has seen sluggish growth in recent years. The company on Wednesday unveiled a new restructuring program to deliver annual cost savings of 400 million pounds by 2021.

Nakibur Rahman said the board of GSK Bangladesh Ltd on Thursday decided to close the drug making factory in Bangladesh.

He said GSK Bangladesh Ltd would continue with its profitable consumer health care business that produces items like Horlicks, Sensodyne and Glaxose-D.

“All of our medicines are substitutable with generic and therefore patients should be able to access a range of suitable alternatives,” Nakibur said. He also said the company’s decision would impact about 1,000 employees. GSK Bangladesh will now seek shareholders nod for a final decision.

“GSK will run pharmaceuticals in our emerging markets region as an integrated operation, putting in place the right commercial structure in markets to deliver a sustainable growth ambition,” Nakibur said without elaborating further.

The state-run Investment Corporation of Bangladesh owns 12 percent stake in the company, while 6 percent of the shares are held by public and different institutions.

By Serajul Quadir

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.